Trial Profile
A randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression with observation only in patients with relapsed or refractory, indolent non-Hodgkin's lymphoma who completed and responded to rituximab-based immunochemotherapy induction and initial 2-year rituximab maintenance therapy administered subcutaneously
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 23 Dec 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Rituximab (Primary) ; Antineoplastics
- Indications Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Registrational; Therapeutic Use
- Acronyms MABCUTE
- Sponsors Roche
- 10 Jul 2018 Status changed from active, no longer recruiting to completed.
- 26 May 2018 This trial has been completed in Lithuania as per Eudra.
- 28 Mar 2018 Planned End Date changed from 14 Aug 2018 to 8 May 2018.